key: cord-0849380-2dz3uj95
authors: Delanghe, Joris R; De Buyzere, Marc L; Speeckaert, Marijn M
title: C3 and ACE1 polymorphisms are more important confounders in the spread and outcome of COVID-19 in comparison with ABO polymorphism
date: 2020-08-01
journal: Eur J Prev Cardiol
DOI: 10.1177/2047487320931305
sha: 2a6e49aed5d6fcc34302210cd376b285f91b7712
doc_id: 849380
cord_uid: 2dz3uj95

nan

by Johns Hopkins were analysed. 2 The time interval since the start of the infection in each country was recorded to synchronize the data. Data on the occurrence of polymorphisms of angiotensin-converting enzyme 1 (ACE1), complement component 3 (C3), galactoside 2-alpha-L-fucosyltransferase 2 (FUT2) were collected from the literature. 3 Only studies with a sufficient sample size (>50 participants) and which were in agreement with the Hardy-Weinberg equilibrium (as a quality check) were used as inclusion criteria in our analysis.

C3 is a central component of the innate immune system. 4 A single base substitution in C3 defines two alleles: slow (S) and fast (F), and three phenotypes (C3 SS, C3 FS and C3 FF). ACE1 is characterized by a deletion/insertion (D/I) polymorphism, which largely determines the ACE expression. ACE1 shows a structural homology with ACE2, the receptor for the SARS-CoV-2 virus. An association between the D-allele of ACE1 and COVID-19 prevalence and mortality has been described. 3 The secretor status (controlled by the FUT2 or Se gene) refers to the presence or absence of ABO blood group antigens in body fluids. People secreting these antigens in their body fluids are referred to as secretors, while people who do not are nonsecretors. The secretor status has important consequences for the immune defence: for example, non-secretors have a reduced norovirus susceptibility. Expression of the Lewis blood group antigens is also affected by the secretor status. 5 In a univariate approach, correlation between COVID-19 prevalence and the A allele was significant: log (prevalence; number of cases/10 6 inhabitants) ¼ 2.00 þ 0.050 (A allele frequency, %) -0.008 (date of first case, days since 1 January 2020), r 2 ¼ 0.122; p ¼ 0.04. Similarly, correlation between the A allele and COVID-19 mortality was significant: log (mortality; number of cases/10 6 inhabitants) ¼ 0.589 þ 0.091 (A allele frequency, %) -0.011 (date of first case, days since 1 January 2020), r 2 ¼ 0.232; p ¼ 0.002. The FUT2 gene did not show a correlation with COVID-19 prevalence/mortality. The A allele showed a strong correlation with C3 polymorphism (S allele) (r 2 ¼ 0.451, p < 0.001). In a multivariate regression analysis for predicting COVID-19 prevalence (Table 1) , a determination coefficient of 0.372 was calculated for the model. Significance of the A allele got lost, whereas C3 and 1 Department of Diagnostic Sciences, Ghent University, Belgium 2 Department of Internal Medicine, Ghent University, Belgium ACE1 polymorphisms were determinants for the COVID-19 prevalence. Similarly, only C3 polymorphism was a significant determinant for COVID-19 mortality (r 2 ¼ 0.480, p < 0.0001) ( Table 2) .

C3 and ACE1 polymorphisms may be regarded as confounders in the spread and outcome of COVID-19. The C3 polymorphism is a representative of the first principal component of European gene frequencies, whereas the ABO*A allele shows a weak association with the sixth principal component. 2 Although we could confirm an association between the A allele and COVID-19 prevalence/mortality in a univariate analysis, the A allele lost its significance when other polymorphisms (C3, ACE) were integrated into the model. Like the majority of genetic polymorphisms, the ABO blood group polymorphism shows an east to west gradient in Europe, 2 which passively comigrates with causal human genetic factors involved in COVID-19. As the A allele was eliminated as a significant determinant in the multivariate analysis, its role in COVID-19 seems to be secondary. Furthermore, the lack of correlation between COVID-19 prevalence/mortality and the FUT-2 polymorphism pleads against a major role for the A allele in COVID-19.

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. 

ABO blood group predisposes to COVID-19 severity and cardiovascular diseases

The history and geography of human genes

COVID-19 infections are also affected by human ACE1

Epub ahead of print 14

Complement C3 and its polymorphism: biological and clinical consequences

Lewis histo-blood group system and associated secretory phenotypes

The author(s) received no financial support for the research, authorship, and/or publication of this article.